Gene therapies for prevalent diseases in Europe – the perfect storm of economic sustainability?
pharmaphorum
OCTOBER 14, 2022
In this article, Research Partnership reviews why the path to commercialisation for the half a dozen approvals in Europe over the last few years has not been smooth, and shares feedback gathered from our payer network on the outlook for gene therapy market access in Europe, especially considering the shift to more prevalent diseases.
Let's personalize your content